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INTRODUCTION
Rheumatic  heart  disease  is  the  most  commonest  acquired  heart 
disease all over the world. 
Mitral Stenosis is almost always rheumatic in origin.  Two third of 
the patients with mitral  stenosis are females and mixed mitral stenosis 
and mitral regurgitation are generally rheumatic in origin;  Very rarely, 
MS is congenital.  Predominant Mitral stenosis occurs in approximately 
40% of patients with rheumatic heart disease.  It remains a major problem 
in developing nations, especially in tropical and semitropical countries.
In Rheumatic stenosis the valve leaflets are diffusely Thickened by 
fibrous tissue and/or calcific deposits.  The mitral commissures fuse, the 
chordae  tendinae  fuse  and  shorten,  the  valve  cusps  become  rigid  and 
these  changes  in  turn,  lead  to  narrowing  at  the  apex  of  the  valve 
Calcification  of  the  stenotic  mitral  valve  immobilizes  the  leaflets  and 
narrows the orifice further.  In normal adults the mitral valve orifice is 4-
6 cm2. In the presence of significant,  i.c., when the orifice is less than 
approximately 2cm2, blood can flow from the to the left ventricle only if 
propelled  by  an  abnormally  elevated  left  atrioventricular  pressure 
gradient, the hemodynamic hall mark  of mitral stenosis.  When the mitral 
valve  opening  is  reduced  to  1cm2,  often  referred  to  as  critical  mitral 
stenosis, A left Atrial pressure of approximately 25 mm Hg is required to 
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maintain a normal cardiac output. The elevated pulmonary venous and 
pulmonary  arterial  wedge  pressures  reduce  pulmonary  compliance, 
contributing to exertional dyspnea. 
Pulmonary Hypertension
The  clinical  and  haemodynamic  features  of  mitral  stenosis  are 
influenced importantly by the level of the pulmonary arterial pressure. 
Pulmonary hypertension results from 
1. Passive backward transmission of the elevated LA Pressure; 
2. Pulmonary venous hypertension (reactive pulmonary hypertension) 
3. interstial odema in the walls of the small pulmonary vessels; and 
4. Organic obliterative changes in the pulmonary vascular bed.
Other pulmonary changes
Fibrous  thickening  of  the  walls  of  the  alveoli  and  pulmonary 
capillaries occur commonly in mitral stenosis.
Pulmonary  function  abnormalities,  like  vital  capacity,  Total  lung 
capacity,  maximum breathing capacity,  and oxygen uptake per unit  of 
ventilation are reduced.  Airway resistance is abnormally increased and 
diffusion capacity is also reduced.   These changes in the lungs are due, to 
increased transudation of fluid from the pulmonary capillaries into the 
interstitial and alveolar spaces.  However, the increased capacity of the 
pulmonary  lymphatic  system  to  drain  excess  fluid  retards  the 
development of alveolar edema. 
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AIMS & OBJECTIVES OF THE STUDY 
1. To know the type of pulmonary dysfunction in rheumatic mitral 
stenosis.
2. Relation between grading of dyspnoea (NYHA Class I to IV) and 
severity of pulmonary dysfunction.
3. Relation between mitral valvular size (orifice size) and severity of 
pulmonary dysfunction. 
4. Relation  between  mitral  valvular  orifice  size  and  grading  of 
dyspnoea.
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REVIEW OF LITERATURE
Rheumatic Fever
Acute Rheumatic fever, a non infectious delayed complication of 
streptococcal sore throat due to group A β hemolytic streptococcus.  0.3% 
of patients only develop rheumatic fever after a streptococcal throat.  
Epidemiology of Rheumatic Fever and heart disease.
Rheumatic Fever is a major cardiovascular health problem in many 
nations of the world.
The incidence and prevalence of Rheumatic Fever world wide are 
enormous.   The  prevalence  of  Rheumatic  Fever  and  RHD  is  highly 
variable,  with  the  highest  rates  in  the  middle  eastern  and sub-saharan 
African regions.  For instance, it is estimated that 3.2 million patients had 
rheumatic heart disease in India in 1991 and atleast two thirds of these 
were young children.  The incidence is  declining in all  over the world 
because of improving socio economic status and reduced crowding and 
increase use of penicillin.
Agent, Host and Environmental Factors
Only  Group  A  β haemolytic  streptococcus  throat  infections  are 
strong  enough  to  induce  an  immunologic  response  are  capable  of 
triggering an episode of Rheumatic fever. Acute Rheumatic Fever usually 
affects children (being most common between 5 and 15) or young adults. 
The environmental factors like crowding, poverty, health education and 
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access  to  medical  cave  continue  to  influence  the  development  of 
Rheumatic Fever.
Social and Economic burden 
India  has  good  epidemilogic  data  on  Rheumatic  fever.   The 
prevalence of Rheumatic fever or Rheumatic heart disease among school 
children is 2 to 11 per 1000, with a mean of 6 per 1000.
Indian  Government  allocates  a  mere  2%  of  budget  for  health 
related activities, compared with 5 to 10% in the developed world.
Pathogenesis
Rheumatic  fever  is  a  immune  (cellular  and  antibody)  mediated 
injury.   The  current  understanding  proposes  that  rheumatogenic 
streptococci contain multiple antigenic determinants that mimic normal 
human tissue antigens; these antigens are recognized as Foreign by the 
susceptible  host  and  result  in  a  hyperactive  immune  response  (both 
humoral and cellular)
Group A polysuccharide has an N-acetyl glucosamine moiety that 
cross reacts with antibodies to the heart valve tissue and patients with 
significant valvular heart disease have an excess of such cross-reactive 
antibodies.   Antibodies  to  the  streptococcal  peptidoglycan  complexes 
have been implicated in rheumatic arthritis.  The streptococcal M protein 
has homology with the cardiac contractile proteins including myosin and 
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tropomyosin and structural proteins like keratin, laminin and vimentin, 
which are common in the cardiac interstitium.
Cellular  immunity  instead  may  contribute  significant  T  cell 
infiltration in the valvular tissue and synovium.  Membrane antigens of 
group A streptococci can stimulate T cell cytotoxic for cardiac but not 
skeletal muscle cell.  
Rheumatic  Fever  risk  has  been  associated  with  increased 
prevalence of HLA- DR4 in the United States and Saudi Arabia and with 
increased prevalence of DR3 and DQW2 in India.  However, DR2 has 
increased prevalence in the African American population in the united 
states, whereas it seems to be protective in Indians.
Pathologic characteristics of cardiac involvement
RF is considered a  multisystem connective tissue disease and is 
characterized by inflammatory, either exudative or  Fibrotic, lesions in a 
number of systems, including the heart, joints and subcutaneous tissue. 
The Aschoff granuloma is the pathologic hall mark of Rheumatic fever. 
It consists of a central area of fibrinoid necrosis surrounded ‘by cells of 
histiocytic – macrophagic origin that show a typical “Owl eye shaped” 
nucleus.   These  cells  are  usually  found  in  the  sub  endocardial  or 
perivascular  regions,  in  the  myocardium  and  sometimes  in  the 
pericardium
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Macroscopic  appearance  is  fibrinous  pericarditis  with  Epicardial 
involvement: 
Pinhead  vegetations  on  valve  leaflet  tissue;  microscopic 
appearance is Fibronoid necrosis in the valve leaflet, cellular infiltrates, 
and neovascularization of  valve.   Macroscopically  valves are  dull  and 
thickened, unlike the smooth pliable normal appearance, and show small 
verrucous vegetations on the atrial surface of the mitral valve, the chords 
and  the  ventricular  surface  of  the  aortic  valve.   The  valves  are 
significantly  inflamed  and  edematous  and  demonstrate  extensive 
pallisading  mononuclear  infiltration.   Aschoff  bodies  are  occasionally 
seen.  There is granulation tissue and fibrous scarring in the late stages of 
the disease.   Aschoff bodies are seen in 30% to 40% of patients with 
proven or suspected carditis. 
Clinical Features
Joint symptoms
Arthritis is a major manifestation of Rheumatic Fever.  Arthritis 
occurs in more than 2/3rd of patients.  Large joints of the extremity are 
usually involved, although smaller joints including those in the hand and 
feet  may occasionally  be inflamed.   Hip and spine  or  axial  joints  are 
rarely involved. The joints are inflamed at various  intervals, each cycle 
lasts  several  days,  and  this  gives  a  migratory  character  to  joint  pains 
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arthritis resolves in most patients within 3 to 4 weeks and does not result 
in any permanent damage.
Carditis
Rheumatic carditis is an early manifestation; almost 80% of patient 
who  develop  carditis  do  so  within  the  first  2  weeks  of  the  onset  of 
Rheumatic Fever.  The most common evidence of carditis is a blowing 
pansystolic  Mitral  regurgitation murmur.   It  is  usually  grade II  to IV, 
radiates  to  the  axilla,  and  sometimes  is  associated  with  apical,  low 
pitched,  short,  middiastolic  rumble  without  a  presystolic  accentuation 
(carey  coombs  murmur).   Valvular  stenosis  does  not  occur  in  Acute 
Rheumatic carditis.  Mitral regurgitation is due to Active inflammatory 
valvulitis,  valve  prolapse,  annular  dysfunction  or  dilatation  and 
ventricular  enlargement.   The  aschoff  nodules  have  a  predilection  for 
valve rings and this may account for annular dysfunction and dilatation.
Myocarditis is often indicated by the presence of a soft first sound, 
gallop  sounds,  cardiomegaly  and  /  or  congestive  cardiac  failure. 
Myocardial biopsies in patient with active rheumatic carditis do not show 
significant  evidence of myocyte damage.  It is now generally believed 
that congestive heart failure in patients with acute rheumatic carditis is 
caused by severe mitral regurgitation.
Clinical rheumatic pericarditis occurs in 6 to 15% of patient during 
the  acute  stage  of  rheumatic  Fever  and  the  presence  of  a  pericardial 
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friction rub in this setting is evidence for rheumatic carditis.  Presence of 
pericarditis indicates severe carditis.
Neurologic manifestation
Chorea is usually a late manifestation and appears several weeks 
after  an  acute  attack  of  Rheumatic  fever  at  a  time  when  other 
manifestation have disappeared and patients often do not fulfill the Jones 
criteria. The onset is usually gradual.  The patient appears increasingly 
nervous, is dysarthric, makes grimacing gestures, had difficulty in writing 
and shows characteristic purposeless movements of the arms and legs. 
These involuntary movements are increased by effort or excitement, are 
absent during sleep, and may be associated with muscular weakness. The 
pathogenesis of chorea remains unclear.  Sydenham’s chorea is usually a 
self limited condition and recovers without residua. 
Skin manifestations
Subcutaneous  nodules,  a  late  manifestation  of  Rheumatic  fever, 
occur in 1% to 21% of patients and the presence of subcutaneous nodules 
usually suggests underlying carditis.  The nodules are firm and painless, 
0.5 to  3 cm and are  usually  on bony proninance or  vertebral  spinous 
processes and on extensor tendons.   They usually appear in crops and 
disappear within 8 to 12 weeks in most patients.
Similar to subncutaneous nodules, erythema marginatum is usually 
indicative  of  underlying  carditis.  Erythema  marginatum,  unlike 
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subcutaneous nodules, however can be an early or a late manifestation 
and can be present in the absence of features to indicate active Rheumatic 
fever.  It occurs in less than 10% to 15 % of patients, is present on the 
trunk  and  proximal  extremities  as  a  serpigenous  macular  non  pruritic 
rash, and is often very evanescent.
Other features 
A number of other signs and symptoms seen in patients with acute 
rheumatic fever and in view of their nonspecific nature are called minor 
manifestation for  diagnostic purposes.   These include fever,  prolonged 
PR interval, and elevated acute-phase reactants.
The Jone’s criteria for diagnosis of acute Rheumatic fever
Major criteria Minor criteria
Carditis Previous Rheumatic Fever or RHD
Polyarthtis Arthralgia
Chorea Fever
Subcutaneous nodules ESR
Erythema marginatum Positive Creative Protein
Leukocytosis
Prolonged PR interval 
Needs two major criteria or one major plus two minor criteria for 
diagnosis.  Needs supportive evidence for recent streptococcal infection 
for all diagnosis.  The ASO titre should be more than 240 units in adults 
15
and more than 330 units in children.   The best diagnostic specificity is 
obtained by demonstrating  an  interval  increase  in  ASO in  two paired 
serial  samples.   Increased ASO titres are seen in within 7 to 10 days. 
Anti  DNase  B  which  remain  elevated  for  several  months  after  even 
uncomplicated streptococcal infections.
Role for Echocardiography
Clinically  detectable  valvular  regurgitation  (Usually  mitral  and 
occasionally Aortic) is the hallmark of Acute carditis. Echo cardiography 
consistently demonstrate valve regurgitation not detectable with clinical 
examination.
Investigations in Acute rheumatic Fever
1. Evidence of a systemic illness (Non specific) Leukocytosis, raised 
ESR, raised CRP.
2. Evidence of proceeding streptococcal infection (specific) Throat 
Swab culture: GroupA β–haemolytic streptococci Antistreptolysin 
O antibodies (ASO titres)
3. Evidence of carditis  
Chest radiograph :  Cardiomegaly; pulmonary congestion
ECG : first  and second degree heart block; features of pericarditis;  T 
wave inversion; reduction in QRS voltages
Echocardiography : Cardiac dilatation and valve abnormalities.
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Chronic rheumatic heart disease
Chromic valvular heart disease develops in at least half of those 
affected by rheumatic fever with carditis.  Two-thirds of cases occur in 
women.  Some episodes of rheumatic Fever may pass unrecognized and it 
is only possible to elicit a history of Rheumatic Fever or chorea in about 
half of all patients with chronic rheumatic heart disease.  The mitral valve 
is  affected  in  more  than  90%  of  cases;  The  aortic  is  the  next  most 
frequently affected valve, followed by tricuspid and then the pulmonary 
valve.  Isolated mitral stenosis accounts for about 25% of all  cases of 
rheumatic disease and an additional 40% have mixed mitral stenosis and 
regurgitation.
Pathology
In contrast to destructive lytic process of acute rheumatic fever, the 
main  pathological  process  in  chronic  rheumatic  heart  disease  is 
progressive  Fibrosis.   The heart  valves are predominantly  affected but 
involvement  of  pericardium  and  myocardian  may  contribute  to  heart 
failure  and conduction disorders.   Fusion of  mitral  valve commissures 
and shortening of the chordae tendineae may lead to mitral stenosis with 
or without regurgitation.  Similar changes in the aortic and tricuspid valve 
produce distortion and rigidity of the cusps, leading to stenosis and or 
regurgitation.
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Pathophysiology
In normal adults the mitral valve orifice is 4-6 cm2.  in the presence 
of significant obstruction, I.e when the orifice is less than approximately 
2cm2, blood flow from the LA to the left ventricle (LV) only if propelled 
by  an  abnormally  elevated  left  atrio-ventricular  pressure  gradient,  the 
hemodynamic  hall  mark  of  mitral  stenosis.   When  the  mitral  valve 
opening is reduced to 1cm2, often referred to as “critical” MS, Left Atrial 
pressure of approximately 25 mm Hg is required to maintain a normal 
cardiac output.  The elevated pulmonary venous and pulmonary arterial 
PA wedge pressure reduce pulmonary compliance, contributing to exert 
ional dyspnea. 
454-D
Symptoms of mitral stenosis
1. Breathlessness
2. Fatigue
3. Oedema, ascites
4. Palpitation
5. Haemoptysis
6. Cough with expectations
7. Chest pain
8. Symptoms  of  Thrombo  embolic  complications  e.g.  Stroke, 
Ischaemic limb)
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Signs of Mitral Stenosis 
1. Atrial fibrillation
2. Mitral facies
3. Auscultation : Loud first heart sound, opening snap, middiastolic 
murmur
4. Signs  of  raised  pulmonary  capillary  pressure,  crepitations, 
pulmonary oedema, effusions.
5. Signs of pulmonary hypertension, RV heave, loud P2 
Investigations in mitral stenosis
ECG
Lt atrial hypertrophy
Right ventricular hypertrophy
Chest radiograph
Enlarged left atium
Signs of pulmonary venous congestion
Echo
Thickened immobile cusps
Reduced valve area
Reduced rate of diastolic filling of LV. According to mitral valve 
orifice area severity of mitral stenosis is graded into 
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1. Mild 1.5 - 2.0 cm2
2. Moderate 1.0 – 1.5 cm2
3. Severe <1 cm2
Doppler
Pressure gradient across mitral valve
Pulmonary artery Pressure.
Cardiac cathetorisation
Pressure gradient between LA (or pulmonary wedge) and LV
Pulmonary function abnormalities
Pulmonary  function  abnormalities  denote  a  disease  of  either 
airways  or  lung  parenchyma  or  both  interfering  with  normal  alveolo-
arterial gas exchange. 
Broadly pulmonary function abnormalities are categorized into 2 
patterns :-
1. Obstructive
2. Restrictive
Obstructive pattern of abnormality is classically observed in cases 
of  chronic  obstructive  pulmonary  disease  (COPD)  whereas  Interstitial 
lung diseases are the prototype for restrictive pattern of abnormality. 
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Patterns of abnormal ventilatory capacity 
FEV1 FVC FEV1/FVC
Obstructive ↓ ↓ ↓ / N ↓
Restrictive ↓ ↓  ↓ ↑ / N
This segregation into either of the pattern is done based on analysis 
of pulmonary function tests which encompasses a multitude of indicators 
as described below:
Pulmonary Function Tests
Even though many tests are present to know the lung dysfunction, 
PFT is easiest and one of the best tests to know ventilation dysfunction.
Definitions
Tital  volume  –  the  amount  of  air  moves  into  lungs  with  each 
inspiration (or exhale in each expiration).
Inspiratory reserve volume
The air inspired with a maximal inspiratory effort in excess of the 
tidal volume. 
Expiratory Reserve Volume
The volume expelled by an active expiratory effort after passive 
expiration
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Residual volume
The Air left in the lungs after a maximal expiratory effort.
Vital Capacity
The  largest  amount  of  air  that  can  be  exhaled  after  a  maximal 
inspiratory effort.
The  fraction  of  vital  capacity  expired  during  the  first  second 
divided by the vital capacity is FEV1. 
Spirometry
Introduction
Spirometry is a test of lung function that measures how much and 
how  quickly  air  can  be  moved  into  and  out  of  the  lungs.   The 
measurements are made using a spirometer.
A spirometer is an instrument used to measure respired volumes 
and flows (i.e. spirometry).  Many spirometers are able to measure both 
inspiratory and expiratory airflow. 
How to perform spirometry
Spirometry requires maximal effort from the patient and it takes 
time  to  perform  quality  spirometry.   It  is  essential  the  procedure  is 
carefully  and clearly  explained and to  actively  coax and motivate  the 
patient  to  perform  maximally.   The  volume  and  flow  parameters 
measured are defined in terms of maximal effort and maximal exhaled 
volume.  The performance of spirometry while seated upright in a chair is 
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preferable to standing as this is the most stable position should the patient 
experience  dizziness  during  the  test.   The  seated  position  is  also 
preferable for patient with urinary incontinence who may otherwise limit 
the expiratory effort.
The key steps are to urge the patient to:
 Breathe in fully (the lungs must be absolutely full).
 Seal the lips around the mouthpiece and immediately.
 Blast the air out as fast and as far as possible until the lungs are 
completely empty.
 Repeat the test until three acceptable and reproducible results are 
obtained (up to a maximum of 8 efforts)
 The highest FEV1 and FVC should be reported, even if they come 
from separate blows.
Contraindications
Spirometry  is  a  very  safe  procedure.   However,  it  is  physically 
demanding  as  it  requires  maximal  patient  effort  and  it  involves  the 
generation of high airway and intrathoracic pressures.  It is advisable that 
spirometry be delayed / abandoned for:
 Recent eye surgery.
 Recent thoracic and abdominal surgery.
 Aneurysms (e.g. cerebral, abdominal).
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 Unstable cardiac function.
 Haemoptysis of unknown cause (e.g.? TB)
 Pneumothorax.
 Chest and abdominal pain.
 Nausea and diarrhoea.
 Inability to comprehend the instructions.
This a simple method for studying the pulmonary ventilation by 
recording the volume movement of air into and out of the lungs. In this 
test, the subject inhales maximally to total lung capacity (TLC) and then 
exhales  as  rapidly  and  forcefully  as  possible  into  the  turbine  of  the 
spirometer,  which calculates the flow rates and volume measurements. 
The flow rates can calculated from the ‘spirogram’ which is a plot of 
volume verses time, and the volume can be calculated from the ‘flow-
volume tracings’ which is a plot of airflow verses the expired or inspired 
lung volume.
Flow rates
Forced Vital Capacity (FVC) is the maximal volume of gas which 
can be expired from the lungs during a forced expiration from a position 
of full inspiration. The FVC can be subdivided into the Forced Expiratory 
Volume in the first second (FEV1), represents the integrated flow over the 
first second of expiration and reflects airway narrowing during expiration. 
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It is effort independent and normally 70% - 80% of the FVC is expired in 
the first second.
A  more  sensitive  means  of  evaluating  airway  obstruction  is 
therefore, to express the forced expired volume as a percentage of vital 
capacity, abbreviated as FEV1% (or FEV1/FVC).  This ratio is relatively 
independent  of  the patient’s  size,  and is  a  specific  measure  of  airway 
obstruction  with  or  without  associated  restriction  of  lung  volumes. 
Normally it is 75% or greater.
Another way of assessing airflow obstruction is to measure specific 
flow  rates.   Peak  Expiratory  Flow  Rate  (PEFR)  is  a  defined  as  the 
maximum  flow  achievable  from  a  forced  expiration  starting  at  full 
inspiration  with  an  open  glottis.  It  measures  the  maximum expiratory 
flow rate over the first 10 millisecond.  PEFR is reduced by larger airway 
narrowing due to asthma, COPD, vocal cord palsy and expiratory muscle 
weakness  etc.   The Forced Expiratory  Flow from 200 ml  to  1200 ml 
below maximal inspiration (FEF2-12) can also be measured.  FEF2-12, also 
called Maximal  Expiratory Flow Rate (MEFR) is used to evaluate the 
portion of the curve most affected by obstruction of large airways and is 
most responsive to bronchodilators.  FEF2-12 and PEFR are useful in the 
diagnosis and response to bronchodilators in asthma and are very much 
effort-dependent.  Flow from 25 to 75 percent of the total FVC, termed 
FEF25%-75% is  another  measurement  which  was  originally  called  as 
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Maximal Mid-expiratory flow Rate (MMFR).  This is effort independent 
and is very sensitive to airflow obstruction in peripheral, small airways, 
where  disease  of  chronic  airflow  obstruction  are  thought  to  begin. 
FEF25%-75% is dependent on FVC, in other words, it is the average flow rate 
during the middle two quarters of FVC.
Flow Volumes
Flow  volume  curve,  a  recording  during  spirometry,  of  the 
expiratory flow plotted against expired volume, instead of time, resemble 
a  triangular  shaped  envelope.   At  the  point  where  25%  of  the  vital 
capacity has been exhaled,  this flow rate is termed V  max25 or FEF  25% 
when 50% of the vital capacity has been exhaled it is termed Vmax50 or 
FEF 50% and at 75 of vital capacity it is vmax75 or FEF 75% which refers to 
the maximal expiratory flow when 75% of FVC remain to be exhaled. 
Similarly  FEF  50%  and  FEF  75%  correspond  to  MEF50%  and  MEF25% 
respectively. 
The inspiratory portion of  the  curve is  helpful  in  distinguishing 
large airway obstruction which occurs above the level of thoracic inlet 
from obstruction which occurs below this level. Large airway obstruction 
above  the  thoracic  inlet  results  in  a  plateau  of  the  flow  rate  on  the 
inspiratory portion of the curve, while the expiratory portion is affected 
when the flow limiting portion is within the thoracic cavity.
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FEF75% is though to be very sensitive to detect early small airway 
obstruction.  In early small airway disease, the only abnormality detected 
may be reduced FEF75% and FEF50% with normal PEFR and FEV1. 
It is a well studied fact that patients with rheumatic mitral stenosis 
are prone to develop pulmonary ventillatory dysfunction and the severity 
of mitral stenosis influence the degree of lung function impairment.
In an analysis of 105 patientgs with rheumatic mitral valve diseases 
[20-21% patients with mitral stenosis and 80-84% with combined mitral 
valve  disease  with  a  stenosis  predominance]  Hryniewiecki  T  et  al. 
observed  that  93.5%  patients  had  documented  airway  function 
disturbance.  Using a diagnostic criteria as MEF 50<60% of predicted 
value, they found out that  peripheral airway obstruction had a significant 
correlation to severity of mitral stenosis.  Also bronchial hyperreactivity 
was  noted  in  23%  patients,  but  main  bronchus  obstruction  was  not 
significantly present in association with any of the analyzed cardiological 
parameters. 
In another study in 60 patients correlating spirometry abnormalities 
with  different  grades  of  severity  of  mitral  stenosis,  Chatterji  et  al., 
observed  that  FVC  values  were  reduced  in  direct  proportion  to  PAP 
(Pulmonary Artery Pressure), LAP (Left Atrial pressure) and Mitral valve 
area (MAV).  FEV 1% was also found to be uniformly reduced according 
to the severity of mitral stenosis and they concluded that mitral stenosis 
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was  associated  with  a  moderate  restrictive  defect  with  an  inverse 
correlation and there was no significant involvement of larger airways.
Mahmoud. M Nour et al, in an analysis comparing patients with 
simple mitral stenosis and those with advanced mitral stenosis scheduled 
for valve replacement surgery (MVR) confirmed that patients with mitral 
stenosis  have  both  restrictive  and  obstructive  pattern  of  pulmonary 
dysfunction which correlated with the severity of mitral stenosis and with 
respiratory symptoms. 
In  another  study  from  the  same  institution  they  illustrated  that 
airway  obstruction  in  mitral  stenosis  in  partially  reversible  with 
salbutamol nebulization in both pre and post MVR operative cases.  This 
implicated  that  in  patients  with  mitral  stenosis  with  dyspnoea,  doing 
pulmonary function test would assist in sorting and patients who can be 
provided  symptomatic  improvement  by  supplementing  salbutamol 
nebulization for the reversible small airway obstruction. 
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MATERIALS AND METHODS
This was a case control – cross sectional study conducted at Govt. 
Rajaji  hospital,  Madurai.   The  study  population was divided into two 
groups.
Group I consisted of 60 Isolated Rh. Mitral stenosis, diagnosed by 
echo  cardiography.   Group  consisted  of  20  Non  smoking,  healthy 
volunteers, who served as controls.
Group I (N=60) inclusion criteria
1. Age - 10-51
2. Sex - Male or Female 
3. Disease - Isolated Rheumatic Mitral stenosis
Exclusion Criteria
1. H/o smoking
2. H/o Alcohol
3. H/o  Any major  illness  or  H/o  hospitalization  during  the  past  6 
months.
4. History, clinical, radiological evidence of respiratory illness. 
5. Past H/o Bronchial asthma, pulmonary tuberculosis, COPD.
6. Aortic valve disease, IHD, uncontrolled hypertension or any other 
congenital heart disease.
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Group II (n = 20) inclusion criteria
1. Age 18-59
2. Sex Male or Female 
3. Non smoker
Exclusion criteria 
1. H/o. smoking
2. H/o. Alcoholism
3. H/o. recent respiratory illness or Recent hospitalization
4. H/o. Cardiovascular disease
5. History, Clinical, radiological evidence of respiratory illness.
6. Past H/o. bronchial Asthma, pulmonary Tuberculosis, COPD
7. X-ray chest abnormalities
8. ECG abnormalities
The patients and controls were evaluated as per the predesigned 
proforma and routine relevant investigations were done to assess their 
cardiac status and pulmonary status.
The routine scheme of evaluation included
1) History
2) General examination
3) Systemic examination
4) ECG
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5) X-ray chest P/A view 
6) Basic haemogram
7) Blood sugar, urea and serum creatinine
8) Echocardiogram
After  assessing  the  baseline  clinical  and  laboratory  parameters 
patients  and  controls  were  subjected  to  computerized  Spiro  metric 
evaluation in batches after obtaining consent.
All the reading were expressed as the percentage of the predicted 
value for that particular Age, sex, height and weight comparable to south 
Indian population defined by Knudsen et al.  Every test was repeated on 
three different occasions and the best of the three reading were taken.
The various spirometric parameters recorded were 
1. Forced vital capacity (FVC)
2. Forced expiratory volume in the 1st Second (FEV1) 
3. Percentage of FVC expelled as FEV1. 
FEV1  x  100
FVC
4. Peak expiratory flow rate (PEFR)
5. Forced expiratory Flow rate at 50%
6. Forced expiratory Flow rate at 75%
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Interpretation
The  Spirometric  readings  are  useful  in  the  interpretation  of  the 
pattern of pulmonary dysfunction.  The various abnormalities are 
I. Restrictive pattern 
Establish restriction – FVC < 80%
II. Obstructive Pattern 
Established obstruction – FEV1/FVC < 75
Early large airway obstruction – PEFR < 70% and 
FEV1  < 80%
Early small airway obstruction – FEF50 < 70%
FEV75 < 70% 
II. Mixed Patter
1. When both FEF/FVC < 75% and FVC <80%
2. When FEFR < 70%, FEF75<70% and FVC < 80%
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RESULTS AND STATISTICAL ANALYSIS
A. COMPARISON OF PARAMETERS IN STUDY CASES AND 
CONTROLS
Table 1
Age
Age Group Study Cases Controls
No. % No. %
< 20 6 10 2 10
20-29 22 36.7 7 35
30-39 20 33.3 7 35
40-49 10 16.7 3 15
50 & above 2 3.3 1 5
Total 60 100 20 100
Mean
S.D.
31.4
9.2
32.3
10.8
‘p’ 0.9734
The mean age of study cases is 31.4 and the mean age of controls is 
32.3.  There is no statistically significant difference in the mean age of 
the study cases and controls.
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Table 2 Sex
Sex Study Cases Controls
No. % No. %
Male 36 60 10 50
Female 24 40 10 50
‘p’ 0.6014
In this study,  total  number  of  study cases  were 60.   Out of 60, 
males were 36 (60%), Females were 24 (40%).  Total number of controls 
were 20, out of 20, males were 10 (50%) females were 10 (50%).  The 
Sex composition of the two groups does not differ significantly.
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Table 3
Parameters Study Cases Controls
p
Mean S.D. Mean S.D.
EVC 40.55 13.1
7
65.6 9.75 0.0001(Significant)
FEV1 57.98 14.5 99.4 12.4
8
0.0001(Significant)
FVC 51.96 13.8
9
87.05 8.2 0.0001(Significant)
PEF 46.97 21.2 74.2 16.2
3
0.0001(Significant)
FEV1/FVC% 114.1
7
6.85 119.2 4.13 0.0073(Significant)
MEF50 60.23 28.5
8
92.4 8.23 0.0001(Significant)
MEF75 48.28 26.9
7
75.25 12.9
5
0.0001(Significant)
There  is  statistically  significant  difference  in  the  pulmonary 
function values between the Study cases and normal cases.
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TABLE 4
INTERPRETATIONS OF CASES IN THE TWO GROUPS
Interpretations Study Cases Controls
No. % No. %
Normal 2 3.3 20 100
Mild Restriction 19 31.7 - -
Moderate 
Restriction 
15 25 - -
Severe 
Restriction 
24 40 - -
‘p’ = 0.0001 ( Significant )
In this study, total number of patient were 60, out of 60, 2 patients 
did not have any pulmonary dysfunction.  Mild restriction was seen in 
31.7% of patients.   Moderate  restriction was seen in 25% of patients. 
Severe  restriction  was  seen  in  40%  of  patients.   No  pulmonary 
dysfunction was seen in controls (20 in No) 
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B.  RELATIONSHIP  OF  VARIOUS  PARAMETERS  WITH 
INTERPRETATION IN THE STUDY CASES
Table 5
Age and Interpretation
Age
Interpretation
Normal Mild 
Restriction
Moderate 
Restriction
Severe 
Restriction
No. % No. % No. % No. %
< 20 (6) - - 3 50 1 16.7 2 33.3
21-30 (22) 1 4.5 7 31.8 6 27.3 8 36.4
31-40 (20) - - 6 30 6 30 8 40
41-50 (10) 1 10 2 20 2 20 5 50
> 50 (2) - - 1 50 - - 1 50
Total (60) 2 3.3 19 31.7 15 25 24 40
Mean age
S.D.
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12.7
30.7
9.5
29.8
8.4
32.4
9.4
0.7298 (not significant)
There  is  no  statistically  significant  difference  in  pulmonary 
function test with respect to age. 
TABLE 6
SEX AND INTERPRETATION
Interpretation
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Sex Normal Mild 
Restriction
Moderate 
Restriction
Severe 
Restriction
No. % No. % No. % No. %
Male (36) 1 2.8 10 27.8 7 19.4 18 50
Female (24) 1 4.2 9 37.5 8 33.3 6 25
P 0.5434 ( not significant )
The total number  of study cases were 60 out of 60, 36 patients 
were Males,  24 patients were female.   Male patients out of 36 female 
patients, 1 patient was (2.8%) found to have normal pulmonary functions. 
10  patients  (27.8%)  were  found  to  have  mild  restriction,  7  patients 
(19.4%) patients were found to have moderate restriction.  18 patients 
were  (50%)  were  found  to  have  severe  restriction.   There  is  no 
statistically significant difference in pulmonary functions owing to gender 
difference. 
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Female patients.
Out of 24 Female patients,  1 patients (4.2%) was found to have 
normal pulmonary function tests.  9 patients (37.5%) were found to have 
mild  restriction.   8  patients  (33.3%)  were  found  to  have  moderate 
restriction.  6 patients (25%) were found to have severe restriction.
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TABLE 7
NYHA AND INTERPRETATION
NYHA Class Interpretation
Normal Mild 
Restriction
Moderate 
Restriction
Severe 
Restriction
No. % No. % No. % No. %
Class I (9) 1 11.
1
6 66.7 2 22.2 - -
Class II (26) 1 3.8 13 50 11 42.3 1 3.8
Class III (25) - - - - 2 8 23 92
P 0.0064 (Significant)
NEWYORK HEART ASSOCIATION CLASSIFICATION
FOR DYSPNOEA.
Class I No symptoms with ordinary physical activity.
Class II Symptoms with ordinary activity, slight limitation of 
physical activity.
Class III Symptoms  with  less  than  ordinary  activity,  marked 
limitation of activity. 
Class IV Symptoms with any physical activity or even at rest.
Out of 60 study cases, 9 patients were with Class I dyspnoea, 26 
patient  were  with  Class  II  dyspnoea,  25  patients  were  with  Class  III 
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dyspnoea.  Class IV dyspnoea patients were not included in this study 
because of they were haemodynamically unstable. 
In this study, Class III dyspnoea patients were (25%) found to have 
severe restrictions (92%) 
Table 7A: NYHA and MVO size
NYHA Class MVO Size
Range Mean S.D
I 0.8 – 1.2 0.96 0.16
II 0.6 – 1.2 0.87 0.16
III 0.52 – 0.9 0.7 0.11
‘p’ 0.0001 (Significant)
Statistically  significant  relationship  exists  between NYHA Class 
and MVO size.
Table 7B: NYHA Class and mean MV Gradient.
NYHA Class Mean MV Gradient
Range Mean S.D
I 8 – 23 13.78 5.45
II 8 – 34 16.92 6.28
III 10 – 32 21.04 6.48
‘p’ 0.0079 (Significant)
As NYHA Class increases, mean MV gradient values also increase. 
This relationship is statistically significant.
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Table 8
Size of MVO (Cm2) and Interpretation
Interpretation Size of MVO (Cm2)
Range Mean S.D.
Mild Restriction 0.8-1.2 0.98 0.15
Moderate 
Restriction
0.7-1 0.81 0.1
Severe 
Restriction
0.52-0.9 0.69 0.11
p 0.0001 ( significant)
As degree of restriction becomes Severe Restriction, mean MVO 
values decrease. This decrease is statistical significant.
Correlation between MVO size and mean MV gradient  (r) = 0.53 r 
> 0.5
MVO size and mean MV gradiant are correlated. 
Table 9
Mean MV Pressure gradient (mm Hg) and Interpretation
Interpretation Mean MV Pressure gradient (mm Hg)
Range Mean S.D.
Mild Restriction 8-23 13.6 4.5
Moderate 
Restriction
10-28 18.7 5.8
Severe Restriction 10-32 21.2 6.1
p 0.0002 (Significant)
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As  the  mitral  valve  pressure  gradient  increases  the  degree  of 
restriction become severe. 
Table 10
LA CLOT AND INTERPRETATION
LA Clot
Interpretation
Normal Mild 
Restriction
Moderate 
Restriction
Severe 
Restriction
No. % No. % No. % No. %
Present (6) - - 1 16.7 - - 5 83.3
Absent(54) 2 3.7 18 33.3 15 27.8 19 35.2
P 0.3067(Not significant)
The patients with left atrial clot found to have Severe restrictive 
pulmonary functions (83.3%). 
Table 11
EVC % and Interpretation
Interpretation EVC %
Range Mean S.D.
Mild Restriction 25-71 47.4 13.2
Moderate 
Restriction
25-67 45.3 11.7
Severe Restriction 15-54 31.9 9.6
p 0.0005 (Significant)
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Table 12
FEV1 and Interpretation
Interpretation FEV1
Range Mean S.D.
Normal 80-90 85 7.1
Mild Restriction 61-74 68.7 4.3
Moderate Restriction 46-69 62.5 7.5
Severe Restriction 24-70 44.4 11.1
p 0.0001 (Significant)
Table 13
FVC and Interpretation
Interpretation FVC
Range Mean S.D.
Normal 72-81 76.5 6.4
Mild Restriction 60-75 64.1 4.5
Moderate Restriction 32-60 55 6.9
Severe Restriction 20-61 38.4 8.8
p 0.0001 (Significant)
Table 14
PEF and Interpretation
Interpretation PEF
Range Mean S.D.
Mild Restriction 20-103 54.4 25.1
Moderate Restriction 21-96 50.2 22.9
Severe Restriction 15-66 38.6 12.8
p 0.1539 (not significant)
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Table 17
FEV1/FVC and Interpretation
Interpretation FEV1/FVC
Range Mean S.D.
Mild Restriction 99-120 111.5 7.5
Moderate Restriction 98-123 114.2 0.7
Severe Restriction 104-125 116.2 6.2
p 0.1053
Table 18
MEF50 and Interpretation
Interpretation MEF50
Range Mean S.D.
Mild Restriction 4-135 64.2 35.8
Moderate Restriction 26-117 70.4 29.3
Severe Restriction 20-89 50.1 18.9
p 0.1503(not significant)
Table 19
MEF75 and Interpretation
Interpretation MEF75
Range Mean S.D.
Mild Restriction 6-137 55.5 33
Moderate Restriction 23-105 55.3 28.1
Severe Restriction 6-90 39.2 19
p 0.2109(not significant)
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STATISTICAL ANALYSIS
This study included 60 Patients of Isolated Rheumatic mitral 
stenosis aged between 10 and 51 years and 20 patients of control between 
18 and 59 years 
Male patients were 36 in group I
Female patients were 24 in group I
In group II (Control), the Male Female ratio was 1:1
There  was  statistically  significant  difference  in  the  pulmonary 
function  values  between  the  study  cases  and  normal  cases  of  the  60 
patients in group I,  2 patient  did not have any pulmonary dysfunction 
whereas 19 patients (31.7%) were found to have mild restrictive pattern 
in pulmonary function, 15 patient (25%) were found to have moderate 
restrictive  pattern,  and  24  patient  40%  were  found  to  have  severe 
restriction.
In  group  II  (Controls),  all  20  patients  were  found  to  have  no 
pulmonary dysfunction.
Spirometric parameters
Controls Vs cases
On studying and comparing the spirometric parameters of controls 
and  cases,  it  was  found  to  have  statistically  significant  reductions  of 
EVC, FEVI, FVC, PEF, FEV1/FVC%, MEF50 and MEF75. 
46
96.7%  of  patients  were  found  to  have  mild  to  severe  form  of 
restriction.
As NYHA class increases, the restriction also increase.
As mitral value size reduces, the restriction also increase.
As the mitral value gradient values increase, grading of dyspnoea 
(NYHA class)  increases  mitral  valve  size  and mean  MV gradient  are 
correlated. 
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DISCUSSION 
The incidence and prevalence of Rheumatic Fever world wide are 
enormous.   The  prevalence  of  Rheumatic  Fever  and  RHD  is  highly 
variable,  with  the  highest  rates  in  the  middle  eastern  and sub-saharan 
African regions.  For instance, it is estimated that 3.2 million patients had 
rheumatic heart disease in India in 1991 and atleast two thirds of these 
were young children.  Rheumatic Fever is a major cardiovascular health 
problem in many nations of the world.
Chronic valvular heart disease develops in at  least  half of those 
affected by rheumatic fever with carditis. Two-thirds of cases occur in 
women.  Some episodes of rheumatic fever may pass unrecognized and it 
is only possible to elicit a history of rheumatic fever or chorea in about 
half of all patients with chronic rheumatic heart disease.  The mitral valve 
is  affected  in  more  than  90%  of  cases;  the  aortic  is  the  next  most 
frequently affected valve, followed by tricuspid and then the pulmonary 
valve.  Isolated mitral stenosis accounts for about 25% of all  cases of 
rheumatic disease and an additional 40% have mixed mitral stenosis and 
regurgitation.
In normal adults the mitral valve orifice is 4-6 cm2.  In the presence 
of significant  obstruction, (when the orifice  is less than approximately 
2cm2), blood flow from the Left Atrium to the left ventricle (LV) only if 
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propelled  by  an  abnormally  elevated  left  atrio-ventricular  pressure 
gradient. This is the hemodynamic hall mark of mitral stenosis.  When 
the mitral valve opening is reduced to 1cm2, often referred to as “critical” 
MS, a Left  Atrial pressure of approximately 25 mm Hg is required to 
maintain a normal cardiac output.  The elevated pulmonary venous and 
pulmonary  arterial  wedge  pressure  reduce  pulmonary  compliance, 
contributing to exertional dyspnoea.
Apical 4 chamber view showing Fish-mouth appearance of severe 
rheumatic mitral
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The Rheumatic mitral stenosis patients are more prone to develop 
pulmonary dysfunction and the severity of mitral stenosis may influence 
the degree of lung function impairment.  The clinical and haemodynamic 
features of mitral stenosis are influenced importantly by the level of the 
pulmonary  arterial  pressure.   Fibrous  thickening  of  the  walls  of  the 
alveoli  and  pulmonary  capillaries  occur  commonly  in  mitral  stenosis. 
Pulmonary function abnormalities, like vital capacity, total lung capacity, 
maximum breathing capacity, and oxygen uptake per unit of ventilation 
are  reduced.   Airway resistance  is  abnormally  increased and diffusion 
capacity  is  also  reduced.    These  changes  in  the  lungs  are  due,  to 
increased transudation of fluid from the pulmonary capillaries into the 
interstitial and alveolar spaces.  However, the increased capacity of the 
pulmonary  lymphatic  system  to  drain  excess  fluid  retards  the 
development of alveolar edema. 
In the present study, 60 Isolated Rheumatic mitral stenosis patients 
regularly attending the medical OPD and cardiology OPD for treatment 
were selected for analysis. To avoid confounding effects of variables like 
smoking,  pulmonary  tuberculosis,  bronchial  asthma  and  respiratory 
infections,  20  non-smoking  age  matched  population  was  selected  as 
control, after excluding the above mentioned factors.  The mean age of 
the patient population was 31.4 years and that of control was 32.3 years.
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The Patient population and controls were matched with respect on 
age  and  sex.   Statistical  analysis  revealed  that  age  and  sex  did  not 
statistically  influence  the  pulmonary  function  abnormalities.    It  was 
observed  that  as  the  valve  orifice  diminishes  there  is  progressive 
restriction in the pulmonary functions.  Also as the mitral valve pressure 
gradient rises the pulmonary functions deteriorate producing progressive 
dyspnoea.  
In  a  study  of  105  patients  with  rheumatic  mitral  stenosis 
Hryniewiecki  T,  et  al.,  demonstrated  that  93.5%  patients  had  lung 
function  impairment  predominantly  restrictive  pattern.  They  observed 
that  as  the severity  of  mitral  stenosis  increases,  there is  a  progressive 
deteriation in the pulmonary function. In our study also, as depicted in 
Fig.7 there was a linear correlation between the severity of mitral stenosis 
and progressive restrictive pattern of pulmonary function abnormalities. 
It  was  documented  in  our  study  that  96.7% of  patients  with  isolated 
rheumatic  stenosis  had  features  of  restrictive  pattern  of  pulmonary 
abnormality.  
The  spirometric  evaluation  of  the  patients  revealed  features  of 
restrictive pattern of pulmonary function abnormality in 96.7% of isolated 
Rheumatic mitral stenosis patient.  Mild restriction was seen in 31.7% of 
patients.    Moderate  restriction  was seen in  25% of  patients.   Severe 
restriction was seen in 40% of patients.  
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The restrictive dysfunction observed in this study was consistent 
with  the  study  done  by  Chattarji  et  al.  They  found  that  a  moderate 
restriction  defect  and  small  airway  defect  which  is  found  in  cases  of 
mitral stenosis, directly correlates to the pulmonary artery pressure, left 
atrial pressure, mitral valve area and transmitral gradient.  There was no 
significant  involvement  of  the  large  airways.   In  our  study  also  as 
demonstrated  in Fig.6 there was an inverse correlation between mitral 
valve orifice area and severity of restrictive pattern of pulmonary function 
abnormalities.
In our study patient’s symptoms according to NYHA classification 
correlated with the progressive  decline  of  pulmonary  function,  mainly 
restrictive.   In  our  study  larger  airways  obstruction  manifesting  as  an 
obstructive  pattern  of  pulmonary  function  of  abnormality  was  not 
observed.  This again is consistent with the previous studies which stated 
that it is the smaller airway disease that dominates in mitral stenosis. 
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LIMITATIONS
1. The study was restricted to the hospital patients.  So if relevance in 
general population is unknown.
2. Though carefully designed and meticulously carried out, the study 
is subject to subject error, instrument error and investigator error. 
3. Class IV dyspnoea patients not included in this study. 
4. Since  the  study  was  a  cross  sectional  analysis,  follow  up  the 
patients  with  treatment  and potential  reversibility  with  usage  of 
bronchodilators  as  quoted  by  Nour  MM,  et  al.  could  not  be 
assessed. 
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CONCLUSION
Our study leads to the following conclusions 
1. Most of the Isolated rheumatic mitral stenosis patients have mild to 
severe restriction of pulmonary function.
2. The  Rheumatic  mitral  stenosis  patients  when  compared  with 
controls, showed statistically significant reduction in EVC, FEVI, 
FVC, PEF, FEVI/FVC%, MEF50 MEF75. 
3. The  degree  of  restriction  is  correlated  with  grade  of  dyspnoea 
(NYHA Class).
4. As  the  mitral  valvular  size  decreases,  the  grading  of  dyspnoea 
(NYHA Class) increases.
5. As the mitral valve gradient increases, the degree of restriction also 
increases.
6. As the mitral valve size decreases, the mean mitral valve gradient 
increases.
7. As valvular size decreases, the degree of restriction increases.
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PULMONARY FUNCTION TESTS IN ISOLATED 
RHEUMATIC MITRAL STENOSIS
1. Name 2. Age 3. Sex
4. H/o. Hypertension, IHD, Aortic Valve disease, or any other congenital 
heart disease, bronchial asthma, pulmonary tuberculosis, COPD, H/o. 
smoking.
5. Any Respiratory disease :
6. Any Specific Complaints :
7. Clinical Features :
a. PR b) BP c) RR d) Chest expansion    e) Temp
f) JVP g) Clubbing h) Dyspnoea NYHA class I) CVS
J) RS k) Abdomen l) Nervous System  
8. Investigations
Alb   TC
a) RBS b) Urine Sugar c) Blood   DC
Deposits   Hb 
d) Blood Urea e)  Serum Creatinine f) ECG
g) X Ray – Chest h) ECHO i) Others
LVIDd        (cm)   LIVDs           (cm)        LVEF      %
RA, RV, LA & LV            
Both the leaflets of MV  
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Thickness MV Score for MS
Subvalvular fusion Mobility Restriction 
LA Clot Calcification
MVO (sq.cm) Pulmonary hypertension
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Fig. 1.  COMPARISON OF AGE BETWEEN CASES AND 
CONTROLS
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Fig. 2    SEX COMPOSITION OF THE STUDY POPULATION 
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Fig. 3  COMPARISON OF PULMONARY FUNCTION   
INDICES BETWEEN CASES AND CONTROLS
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Fig. 4.  PIE CHART SHOWING DISTRIBUTION OF 
ABNORMALITIES IN PULMONARY FUNCTION TEST  IN   
CASES AND CONTROLS   
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Fig. 5  CORRELATION OF SEVERITY OF SYMPTOMS AND   
ABNORMALITIES IN PULMONARY FUNCTION TEST   
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Fig. 6.   CORRELATION BETWEEN   SIZE OF MITRAL VALVE  
ORIFICE AND PULMONARY FUNCTION 
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Fig. 7.  CORRELATION OF MEAN MITRAL  VALVE PRESSURE 
GRADIENT (MVPG) AND PULMONARY FUNCTION TEST
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